Pfizer (NYSE:PFE)

Short Sellers Hike Bets in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Apple Isn’t the Only Dow Stock That Analysts Are Thrilled About

This current earnings season has been a roller-coaster for Dow stocks. Although a few have underperformed, there have been a couple that have completely changed the game. In the final ...
Read Full Story »

Pfizer, UnitedHealth Help Buoy DJIA Thursday

August 3, 2017: Markets opened mixed Thursday and none of the major indexes showed much inclination to stray very far from the break-even line. New claims for unemployment benefits came ...
Read Full Story »

Why Analysts Are Growing More Bullish on 3 Dow Stocks That Aren’t Apple

This earnings season has been absolutely explosive for Dow stocks. Last week Boeing knocked it out of the park and the stock rose over 13%, and this week Apple helped ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Pfizer, Royal Caribbean, Shopify, Under Armour, Walmart and More

Stocks were indicated to open higher yet again on Wednesday for all-time highs on the Dow and S&P 500, with the Dow challenging 22,000 for the first time ever after ...
Read Full Story »

Why Pfizer Earnings Aren’t Exciting Investors

Pfizer Inc. (NYSE: PFE) reported second-quarter 2017 results before markets opened Tuesday. The pharmaceuticals giant reported adjusted diluted earnings per share (EPS) of $0.67 and revenues of $12.9 billion. In ...
Read Full Story »

Apple, Tesla and More Companies Reporting This Week

The second week of earnings season is in the books, with some spectacular successes and miserable failures. The Dow hit a new all-time high this past week on the back ...
Read Full Story »

Major Pharma Short Interest Takes a Big Step Back

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

The Stock Market Is Very Expensive: 5 Safe Blue Chips to Buy Now

By any measure, the eight-and-a-half-year-old bull market is getting tired, and after one of the biggest percentage runs in stock market history, it may be time for investors to move ...
Read Full Story »

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) a close ...
Read Full Story »

Top Analyst Upgrades and Downgrades: BHP Billiton, HP, Kinder Morgan, Marathon Petroleum, Nike, Pfizer, Rite Aid, Tesla and More

Stocks were indicated marginally higher on Thursday after the European Central Bank statement remained quite dovish. The major equity indexes all remain just under all-time highs. Even though this bull ...
Read Full Story »

IBM, JPMorgan Weigh on DJIA Monday

July 17, 2017: Markets opened mixed Monday and never strayed far from the break-even line. The best performing sectors were Utilities and consumer discretionaries while healthcare was the laggard. WTI ...
Read Full Story »

Major Pharma Short Sellers Become More Selective

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

FDA Issues an Approval Not Seen in Almost 20 Years

In an incredible move on Friday, the U.S. Food and Drug Administration (FDA) approved Endari for the treatment of patients age five and older with sickle cell disease to reduce ...
Read Full Story »

Short Sellers Run for Cover From Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »